Intellia Therapeutics, Inc

Intellia's 36.77% short interest is remarkably elevated, suggesting significant skepticism about this unprofitable gene-editing biotech's near-term prospects. Trading well below its 52-week high with an RSI of 47 indicates the stock has room to move in either direction without oversold/overbought extremes. The absence of a P/E ratio confirms Intellia remains pre-profitability, making it a classic high-risk, high-reward play dependent on clinical trial success rather than current earnings power. The substantial short position creates squeeze potential if positive pipeline news emerges, though the company's cash burn rate and competitive CRISPR landscape remain fundamental headwinds that shorts are clearly betting against.